

526 Rec'd PCT/PTO 19 OCT 2008

ATTORNEY'S DOCKET NO.  
ERKHOV-1 (PCT)TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/673686

INTERNATIONAL APPLICATION NO.  
PCT/RU98/00143INTERNATIONAL FILING DATE  
MAY 18, 1998PRIORITY DATE CLAIMED  
APRIL 20, 1998

## TITLE OF INVENTION

METHOD FOR PRODUCING A SPECIFIC ANTISERUM AGAINST THE UNIVERSAL TUMOROUS ANTIGEN AND METHOD FOR DIAGNOSING MALIGNANT TUMOURS USING SAID ANTISERUM

## APPLICANT(S) FOR DO/EO/US

VALENTIN SERGEEVICH ERKHOV



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371 (f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).
4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau)
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has **NOT** expired.
  - d.  have not been made and will not be made.
8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11. to 16. below concern other document(s) or information included:

11.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.  A **FIRST** preliminary amendment.  
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14.  A substitute specification.
15.  A change of power of attorney and/or address letter.
16.  Other items or information:

Small Entity Declaration, Form 210  
Copy of WO cover page

APPLICATION NO. (if known, see 37 CFR 1.5) <b>09/673686</b>	INTERNATIONAL APPLICATION NO. PCT/KR98/00143	ATTORNEY'S DOCKET NO. ERKHOV-1 (PCT)		
<input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS			
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b>	PTO USE ONLY			
Search Report has been prepared by the EPO or JPO.....\$860.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) .....\$710.00				
Neither international preliminary examination fee paid (37 CFR 1.82) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1000.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$100	\$1,000.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(e)).				
Claims	Number Filed	Number Extra	Rate	
Total Claims	4 - 20 =	- 0 -	X \$18.00	\$
Independent Claims	2 - 3 =	- 0 -	X \$80.00	\$
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$ 500.00	
<b>SUBTOTAL =</b>			\$ 500.00	
Processing fee of \$130.00 for furnishing the English translation later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(f)). +			\$	
<b>TOTAL NATIONAL FEE =</b>			\$ 500.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			See cover sheet attached to assign \$ to be charged to Deposit Acct	
<b>TOTAL FEES ENCLOSED =</b>			\$ 500.00	
			Amount to be: refunded	\$
			charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$500.00</u> to cover the above fees is enclosed.				
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 03-2468 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.				
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2468. A duplicate copy of this sheet is enclosed.				
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>				
SEND ALL CORRESPONDENCE TO: COLLARD & ROE, P.C. 1077 Northern Boulevard Roslyn, New York 11576-1696 (516) 365-9802				
 <b>Signature</b> <u>Edward R. Freedman</u> Reg. No. 26,048				
<b>Express Mail No. EL 621 998 742 US</b> <b>Date of Deposit October 19, 2000</b>				
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date indicated above, and is addressed to the Ass't. Commissioner for Patents, Washington, D.C. 20231				
 Lisa L. Vulpis				